NICE funding impacts treatment sequencing patterns in chronic myeloid leukaemia (CML)
08 July 2020
- NICE recommendations determine access to tyrosine kinase inhibitors (TKIs)
- Median duration of treatment by line also decreased as more TKIs were recommended by NICE
- Promisingly, the study also found that the proportion of patients in major molecular response increased by line
Click here to read the abstract in the British Journal of Haematology (abstract number: BSH2020‐EP‐027)
About SVMPharma
SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real-World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.
For more information, please visit www.svmpharma.com and contact us at enquiry@svmpharma.com
ref: APR2020LN003